Travelling Posted - 1 month ago

$KNTE $alejos11 called this at 4.18 - another fail

DonCorleone77 Posted - 1 month ago

$XOMA $KNTE Xoma announces closing of tender offer 09:14 XOMA Corporation announced the Company has completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma common stock for a price per share of $2.5879 in cash, plus one non-tradeable contingent value right representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024. The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024. As of the Expiration Date, a total of 38,258,681 shares of Kinnate common stock were validly tendered, and not validly withdrawn, representing approximately 81% of the outstanding shares of Kinnate common stock as of the Expiration Date....

Scientwist Posted - 1 month ago

$KNTE Halt? News? Anyone know why?

tradethehalt Posted - 1 month ago

$KNTE trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $2.65 Vol: 2.81M.

HaltTradeAlert Posted - 1 month ago

$KNTE Halt Time: 19:50:00 Issue Symbol: KNTE Reason Code: T12 Stock Price: $2.6500 Market Cap: 124.991M Volume: 2,121,570 Relative Volume: 5.78 Shares Float: 22.68M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

Mergerbrief Posted - 1 month ago

$KNTE $XOMA - Tender Offer Expires Mergerbrief.com

Eugene_O Posted - 2 months ago

$KNTE Tender?

Scientwist Posted - 2 months ago

$KNTE Kinnate's sale of oncology assets to Pierre Fabre for up to $31M plus costs represents a strategic refocus. Shareholders, this move promises future financial returns tied to milestones and sharpens our core mission. Optimism is warranted as we advance. Patience and focus will guide us through this promising transition. They must know something w don’t know…. Yet. #KNTE now Neutral.

Tradingmamaj Posted - 2 months ago

$KNTE this may be a stupid question but why would anyone be buying this over the $2.58 max buyout price? The CVR based on today’s news? This scenario is new to me. Thanks.

Ninja_Tradez Posted - 2 months ago

📢 $KNTE - Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories https://newsfilter.io/a/4c897e67603f26ad89b44868e3b263ae

Stock_Titan Posted - 2 months ago

$KNTE Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories https://www.stocktitan.net/news/KNTE/kinnate-biopharma-inc-sells-its-investigational-pan-raf-inhibitor-vegj5eyb4ipl.html

Fallingknife Posted - 3 months ago

$KNTE I am not selling my shares. If they want, they will have to come to my basement to get it!!

Digital_Waffle_Pirate Posted - 3 months ago

$KRON More 13s a few days later, a notable transaction- Nextech Invest, with Kronos Bio since its Series A private financing, unloaded its entire position in Q4 - they made the same move with their stake in $KNTE. I know I've got a tinfoil hat on this weekend, but c'mon.

johsmith Posted - 3 months ago

$KNTE https://www.prnewswire.com/news-releases/kuehn-law-encourages-knte-fang-hayn-and-vine-investors-to-contact-law-firm-302064190.html

LabPsycho Posted - 3 months ago

$KRON XOMA just bought $KNTE for about $2.50/share. KNTE comparable to KRON but KRON has more $$. By compariso this transaction should make $KRON value minimum of $3.50/share

briefingcom Posted - 3 months ago

$XOMA to acquire Kinnate Biopharma ($KNTE) for between $2.3352 and $2.5879 in cash per share plus a contingent value right https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240216080337KNTE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

MuesLee Posted - 3 months ago

$KNTE What is that contingent value right about? Will I hold that new "pseudo-stock" after the merger plus some cash and within one year I got the proceeds from the both sales as kind of a second buy-out-price for that "pseudo-stock"?

valorallure Posted - 3 months ago

$KNTE Tender offer by March 4th. I think we tender for closer to $2.50 area. I was hoping for a higher price as I'm in at $2.47 but glad I can exit at hopefully a small profit.

OpenOutcrier Posted - 3 months ago

$KNTE (halted pre) Kinnate Biopharma Inc. Enters into Agreement to be Acquired by $XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share - SI https://ooc.bz/l/25262

TheTradeXchange Posted - 3 months ago

$KNTE - Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

Stock_Titan Posted - 3 months ago

$KNTE Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share https://www.stocktitan.net/news/KNTE/kinnate-biopharma-inc-enters-into-agreement-to-be-acquired-by-xoma-uuxrgdrbh2dk.html

oakly1b Posted - 3 months ago

$KNTE halted..

HaltTradeAlert Posted - 3 months ago

$KNTE Halt Time: 07:55:00 Issue Symbol: KNTE Reason Code: T1 Stock Price: $2.2700 Market Cap: 106.946M Volume: 59,426 Relative Volume: 0.17 Shares Float: 23.14M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

johsmith Posted - 3 months ago

$KNTE I think we will know more on the 25th March. Until then nothing will happen

valorallure Posted - 3 months ago

$KNTE 10-K should be out any day now with hopefully an 8-K with any updates. Let's get this one sold! Patiently waiting.

valorallure Posted - 01/30/24

$AVRO Reverse mergers are always the biggest risk in these biotech strategic alternatives plays. No matter how far below net cash biotechs sale, always have try to avoid the ones where reverse merger is a risk. I like the ones with large controlling shareholders. Particularly ones where the shareholder has already stated their interest. See $KNTE or $NGM.

Scientwist Posted - 01/30/24

$KNTE Diving into latest moves: Positive vibes from their IND application for the new lung cancer drug KIN-8741, signaling progress. 📉 However, the pivot away from exarafenib and the search for strategic options for KIN-3248 amid mixed trial results paint a complex picture. There shift suggests a strategic reevaluation, with an eye on partnerships to leverage strengths. Market watchers should keep tabs on how these developments influence technicals, as fundamentals take a new turn. Stay alert for volatility. Small position.. slight bearish actually on the science. Due to uncertainty and strong resistance starting at 2.50 that’s where I’m going to set my stop order and cash out, even if this is one of the few Pennies that may be undervalued with a great P/B ratio my over all lean is hold but I think I’ll reinvest my gains. Thank you Kinnate Bio. I know you will do well with one of your deep pipeline projects. On watch list. #Neutral

valorallure Posted - 01/29/24

$KNTE I'd like to see an official announcement that company is halting development of its pipeline while it explores strategic alternatives. I'd also like to see the company go private before end of Q1 2024.

johsmith Posted - 01/28/24

@LabPsycho This was not a $KNTE move. Investors contacted $KNTE that they are interested to take the company private, because they think the inner value is much higher than the current stock price.

LabPsycho Posted - 01/25/24

$KRON Needs to pull a $KNTE move and say they are open to a sale. That alone caused KNTE to double from1.2 to 2.4....KNTE was very comparable to KRON cash / shares / product development at the time.